華魯恆升(600426.SH):成功研發電子級碳酸甲乙酯和碳酸二乙酯產品
格隆匯1月17日丨華魯恆升(600426.SH)宣佈,公司於近日成功研發了電子級的碳酸甲乙酯和碳酸二乙酯產品(簡稱“新產品”),上述產品的研發成功,豐富了公司在新能源領域的產品結構,延伸了產業鏈條。
公司新產品生產工藝採用酯交換技術,結合國內外電解液市場對產品質量的關鍵指標要求,通過調整提升,並經分析檢測,試驗裝置已經打通工藝流程,產品質量已達到電子級的標準,目前正在進一步優化中。
新產品成功研發後,公司已具備三種電解液溶劑的生產能力,提升了一體化市場運營能力與“一攬子”服務能力,將推動公司順利切入新能源市場領域,在助力新能源行業快速發展的同時,也將為企業後續轉型升級發展奠定堅實的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.